

Date: 24<sup>th</sup> November, 2021

<b>BSE Limited</b> 1 <sup>st</sup> floor, New Trading Ring Rotunda Bldg, P.J Towers Dalal Street, Mumbai -400 001	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor Plot No. C/1, G. Block Bandra Kurla Complex Bandra (East), Mumbai – 400 051
<b>Script Code: 500259</b>	<b>Script Code: LYKALABS</b>

Dear Sir/Madam,

**Sub: Public Announcement to Equity Shareholders of Lyka Labs Limited ( “Target Company”)**

M/s Ipcal Laboratories Limited (“the Acquirer”) has received a letter on November 24, 2021 from non-promoter public shareholders of the Target Company (“Sellers”) offering and agreeing to sell / transfer in aggregate upto 48,00,000 Equity Shares representing 16.73% of fully paid-up Equity Share capital and voting capital of the Target Company through Stock Exchange mechanism under block deal / normal market. Accordingly, on November 24, 2021, the Acquirer acquired in aggregate upto 48,00,000 Equity Shares of the Target Company from the Sellers.

Further, the promoters of the Target Company, vide a Joint Management Control agreement (“JMC Agreement”) dated November 24, 2021 executed with the Acquirer, have agreed to classify the Acquirer as a co-promoter alongwith the existing promoters and also share joint management control over the Target Company with the Acquirer.

Pursuant to the above acquisition of purchase orders to be placed for the acquisition of Equity Shares of more than the threshold limit under the SEBI SAST Regulations by the Acquirers in the Target Company and the JMC agreement, this mandatory Open Offer is being made by the Acquirer to the public shareholders in compliance with Regulations 3(1) and (4), 13(2) and other applicable provisions of the SEBI SAST Regulations.

Thanking you,

For Lyka Labs Limited

  
Piyush G. Hindia  
Company Secretary & Compliance Officer  
ACS- 5861

